VERIPRED 20 Rx
Generic Name and Formulations:
Prednisolone (as sodium phosphate) 20mg/5mL; soln; dye- and alcohol-free; grape-flavor.
Indications for VERIPRED 20:
See literature. Individualize. Initially 5–60mg/day.
See literature. Individualize. Initially 0.14–2mg/kg/day in 3–4 divided doses.
Systemic fungal infections. Live vaccines.
May increase risk and mask signs of infection. Tuberculosis. Latent amebiasis. Strongyloides infestation. Ocular herpes simplex. Cerebral malaria. If exposed to chickenpox or measles, consider prophylaxis with immunoglobulin. Supplement with additional steroids in physiologic stress. Hypertension. Renal insufficiency. CHF. Hypothyroidism. Cirrhosis. Kaposi's sarcoma. Ulcerative colitis if perforation pending. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Osteoporosis. Diabetes. Avoid abrupt cessation. May cause electrolyte imbalances, adrenocortical insufficiency, psychotic derangements. Use lowest effective dose. Monitor weight, growth, fluid and electrolyte balance, intraocular pressure. Elderly. Pregnancy (Cat.C). Nursing mothers.
Barbiturates, hydantoins, rifampin, ephedrine, other hepatic enzyme inducers may decrease effects. Potentiated by ketoconazole, estrogens (eg, oral contraceptives). Potentiates and potentiated by cyclosporine. Increased risk of GI effects with aspirin or other NSAIDs. Monitor oral anticoagulants. Excretion of salicylates may be increased. Caution with K+ depleting agents (eg, diuretics, amphotericin-B), digoxin, aspirin in hypoprothrombinemia. Withdraw anticholinesterases at least 24 hours before starting steroids. Adjust antidiabetic agents. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, CHF, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- Ketamine in Electroconvulsive Therapy Accelerates Antidepressive Effects
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children